Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | FAP | Q12884 | 1/20 | 0.45 |
| ▸ | STAMBP | O95630 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27387111 | 1.00 | ACE (0.55) | ACEGLAMAPTRAB9AMEN1 | |
| SCHEMBL28138297 | 0.88 | ACE (0.61) | ACERAB9AMEN1KMT2AHPGD | |
| SCHEMBL28138300 | 0.88 | ACE (0.61) | ACERAB9AMEN1KMT2AHPGD | |
| SCHEMBL24235727 | 0.83 | MEN1 (0.52) | ACEGLAMAPTMEN1KMT2A | |
| SCHEMBL14729351 | 0.83 | ALDH1A1 (0.47) | ACEMAPTMEN1KMT2AHPGD | |
| SCHEMBL7717867 | 0.82 | MEN1 (0.48) | ACEGLAMAPTRAB9AMEN1 | |
| SCHEMBL23446023 | 0.82 | SYK (0.52) | ACEMAPTMEN1KMT2AHPGD | |
| SCHEMBL24235647 | 0.82 | ACE (0.54) | ACEMAPTMEN1KMT2AHPGD | |
| SCHEMBL10825301 | 0.82 | ACE (0.51) | ACEMAPTMEN1KMT2AHPGD | |
| SCHEMBL23446025 | 0.82 | ALDH1A1 (0.49) | ACEMEN1KMT2AHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436691-B1 | CONJUGATE WHICH IS SUBSTANTIALLY NON-IMMUNOGENIC IN HUMANS COMPRISING TARGETING MOIETY CAPABLE OF BINDING WITH TUMOR ASSOCIATED ANTIGEN LINKED TO MUTATED FORM OF CARBOXYPEPTIDASE B ENZYME CAPABLE OF CONVERTING PRODRUG INTO ANTICANCER DRUG | ZENECA LIMITED (GB) | 2002-08-20 | — | — | US | disclosed |
| US-5985281-A | ANTIBODY DIRECTED ENZYME PRODRUG THERAPY (ADEPT) USING A NON-NATURALLY OCCURING MUTANT FORM OF A HOST ENZYME, ESPECIALLY A MUTANT FORM OF RIBONUCLEASE. | ZENECA LIMITED (GB) | 1999-11-16 | — | — | US | disclosed |
| EP-0844885-A2 | CHEMICAL COMPOUNDS | ZENECA LIMITED (GB) | 1998-06-03 | — | — | EP | disclosed |
| WO-1997007769-A2 | CHEMICAL COMPOUNDS | ZENECA LIMITED (GB) | 1997-03-06 | — | — | WO | disclosed |